IRELAND — APC Microbiome Ireland, a world leader in microbiome research has partnered with animal health company animal health company to advance research in antibiotics alternatives.
According to APC, overuse of antibiotics in the food chain is a critical issue for human health due to the increasing number of antibiotic-resistant bacteria or “superbugs”, causing potentially untreatable life-threatening infections in people.
To minimize the risks, regulators worldwide are restricting the use of antibiotics in animals used in food production.
To address the challenge of overuse of antibiotics and still ensure dairy productivity is boosted, the two institutions have said that they will partner to produce scientifically-proven and practical products that improve the health and productivity of the dairy and beef cattle.
The collaborative research project, led by Dr. Des Field and Professor Paul Ross in the APC, will see ImmuCell Corporation benefit from APC’s capabilities and IP relevant to animal health, built-up (in collaboration with Teagasc) over many years.
These include patented microbiome-derived solutions for bovine mastitis and know-how of bioengineering antimicrobial peptides for increased efficacy.
Through the collaboration, ImmuCell’s proprietary Nisin production strain will be developed using APC technology to enhance its production and activity in targeted ways, as a second-generation mastitis product.
Bovine mastitis is an infection that occurs in dairy cattle, where inflammation of the mammary gland and udder can damage milk-secreting tissues.
It is regarded as one of the most economically damaging diseases in the dairy industry globally, and its prevalence is rising across the world.
Commenting on the partnership, Professor Ross, APC Director said: “There is an urgent need for alternatives to antibiotics, particularly in the field of animal healthcare where there is a major dependence.”
“APC Microbiome Ireland is delighted to be embarking on this exciting project with the knowledge-based company Immucell that will see the development of natural antimicrobials (bacteriocins) for the treatment and prevention of mastitis – the most persistent disease of dairy cows.”
On his part, Michael F. Brigham, President and CEO of Immucell said; “We are thankful to enter into this forward-looking collaboration with APC, as we work to complete the FDA regulatory development process for Re-Tain and approach market launch”.
Liked this article? Subscribe to Food Business Africa News, our regular email newsletters with the latest news insights from Africa and the World’s food and agro industry. SUBSCRIBE HERE